MiMedx Group (MDXG) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed MiMedx Group (MDXG) over the past year, gaining 166.3% versus a loss of 34.9%. Over five years, MDXG leads with a -31.7% price change compared with -53.3% for OABI. OmniAb is the larger company by market cap ($705.1 million vs $682.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXG | OABI |
|---|---|---|
| Share price | $4.68 | $4.85 |
| Market cap | $682.24M | $705.14M |
| 1-day change | +1.19% | +4.08% |
| YTD return | -31.76% | +151.89% |
| 1-year return | -34.93% | +166.29% |
| 5-year return | -31.66% | -53.26% |
| P/E ratio (TTM) | 116.88 | — |
| Forward P/E | 23.38 | — |
| EPS (TTM) | $0.04 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.97 | $5.43 |
| 52-week low | $3.03 | $1.30 |
| Distance from 52-week high | -41.34% | -10.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +58.29% | +71.75% |
| Average volume | 1.23M | 1.47M |
| Shares outstanding | 145.93M | 145.39M |
| Employees | 808 | 89 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed MDXG by 201.2 percentage points over the past year.
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
MDXG vs OABI FAQ
Which is bigger, MiMedx Group or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $705.14M compared with $682.24M for MiMedx Group (MDXG).
Which stock has performed better over the past year, MDXG or OABI?
OABI returned +166.29% over the past 12 months, compared with -34.93% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are MiMedx Group and OmniAb in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for MiMedx Group and Biotechnology: Commercial Physical & Biological Resarch for OmniAb.